These increases of PD-1 expression in CD8+ T cells highlight a possible cause for the relapse of tumor growth in this vaccination scenario, suggesting the use of a combination therapy that includes targeting PD-1 with antibody therapy. The gene discussed is PDCD1; the disease is neoplasm.